Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Metab Brain Dis ; 36(5): 1015-1027, 2021 06.
Article in English | MEDLINE | ID: mdl-33620579

ABSTRACT

Maple syrup urine disease (MSUD) is a genetic disorder that leads the accumulation of branched-chain amino acids (BCAA) leucine (Leu), isoleucine, valine and metabolites. The symptomatology includes psychomotor delay and mental retardation. MSUD therapy comprises a lifelong protein strict diet with low BCAA levels and is well established that high concentrations of Leu and/or its ketoacid are associated with neurological symptoms. Recently, it was demonstrated that the phenylbutyrate (PBA) have the ability to decrease BCAA concentrations. This work aimed the development of lipid-based nanoparticles loaded with PBA, capable of targeting to the central nervous system in order to verify its action mechanisms on oxidative stress and cell death in brain of rats subjected to a MSUD chronic model. PBA-loaded nanoparticles treatment was effective in significantly decreasing BCAA concentration in plasma and Leu in the cerebral cortex of MSUD animals. Furthermore, PBA modulate the activity of catalase, superoxide dismutase, glutathione peroxidase and glutathione reductase enzymes, as well as preventing the oxidative damage to lipid membranes and proteins. PBA was also able to decrease the glial fibrillary acidic protein concentrations and partially decreased the reactive species production and caspase-3 activity in MSUD rats. Taken together, the data indicate that the PBA-loaded nanoparticles could be an efficient adjuvant in the MSUD therapy, protecting against oxidative brain damage and neuroinflammation.


Subject(s)
Amino Acids, Branched-Chain/blood , Cerebral Cortex/drug effects , Maple Syrup Urine Disease/metabolism , Nanoparticles/administration & dosage , Oxidative Stress/drug effects , Phenylbutyrates/administration & dosage , Animals , Catalase/metabolism , Cerebral Cortex/metabolism , Glutathione Peroxidase/metabolism , Maple Syrup Urine Disease/blood , Maple Syrup Urine Disease/chemically induced , Rats , Rats, Wistar , Superoxide Dismutase/metabolism
2.
Neurochem Res ; 43(2): 477-487, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29209877

ABSTRACT

Haloperidol is a widely used antipsychotic, despite the severe motor side effects associated with its chronic use. This study was carried out to compare oral dyskinesia induced by different formulations of haloperidol-loaded nanocapsules containing caprylic/capric triglycerides, fish oil or grape seed oil (GSO) as core, as well as free haloperidol. Haloperidol-loaded lipid-core nanocapsules formulations were prepared, physicochemical characterized and administered (0.5 mg kg-1-ip) to rats for 28 days. Oral dyskinesia was evaluated acutely and subchronically and after that cell viability and free radical generation in cortex and substantia nigra. All formulations presented satisfactory physicochemical parameters. Acutely, all formulations were able to prevent oral dyskinesia development in comparison to free haloperidol, except haloperidol-loaded nanocapsules containing GSO, whose effect was only partial. After subchronic treatment, all haloperidol-loaded nanocapsules formulations prevented oral dyskinesia in relation to free drug. Also, haloperidol-loaded nanocapsules containing fish oil and GSO were more effective than caprylic/capric triglycerides nanocapsules and free haloperidol in cell viability preservation and control of free radical generation. Our findings showed that fish oil formulation may be considered as the best formulation of haloperidol-loaded lipid-core nanocapsules, being able to prevent motor side effects associated with chronic use of antipsychotic drugs, as haloperidol.


Subject(s)
Anti-Dyskinesia Agents/pharmacology , Dyskinesias/drug therapy , Fish Oils/chemistry , Haloperidol/pharmacology , Nanocapsules/therapeutic use , Plant Oils/chemistry , Vitis/chemistry , Animals , Biological Products/pharmacology , Cell Survival/drug effects , Dyskinesias/metabolism , Fishes , Male , Rats, Wistar
3.
Mol Neurobiol ; 54(6): 4496-4506, 2017 08.
Article in English | MEDLINE | ID: mdl-27356917

ABSTRACT

Sarcosine is an N-methyl derivative of the amino acid glycine, and its elevation in tissues and physiological fluids of patients with sarcosinemia could reflect a deficient pool size of activated 1-carbon units. Sarcosinemia is a rare inherited metabolic condition associated with mental retardation. In the present study, we investigated the acute effect of sarcosine and/or creatine plus pyruvate on some parameters of oxidative stress and energy metabolism in cerebral cortex homogenates of 21-day-old Wistar rats. Acute administration of sarcosine induced oxidative stress and diminished the activities of adenylate kinase, GAPDH, complex IV, and mitochondrial and cytosolic creatine kinase. On the other hand, succinate dehydrogenase activity was enhanced in cerebral cortex of rats. Moreover, total sulfhydryl content was significantly diminished, while DCFH oxidation, TBARS content, and activities of SOD and GPx were significantly enhanced by acute administration of sarcosine. Co-administration of creatine plus pyruvate was effective in the prevention of alterations provoked by sarcosine administration on the oxidative stress and the enzymes of phosphoryltransfer network. These results indicate that acute administration of sarcosine may stimulate oxidative stress and alter the energy metabolism in cerebral cortex of rats. In case these effects also occur in humans, they may contribute, along with other mechanisms, to the neurological dysfunction of sarcosinemia, and creatine and pyruvate supplementation could be beneficial to the patients.


Subject(s)
Cerebral Cortex/metabolism , Cerebral Cortex/pathology , Energy Metabolism , Oxidative Stress , Sarcosine/administration & dosage , Adenylate Kinase/metabolism , Animals , Creatine Kinase/metabolism , Fluoresceins/metabolism , Glutathione Peroxidase/metabolism , Models, Biological , Oxidation-Reduction , Rats, Wistar , Superoxide Dismutase/metabolism
4.
Metab Brain Dis ; 30(5): 1167-74, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26002427

ABSTRACT

Maple Syrup Urine Disease (MSUD) is a metabolic disorder caused by a severe deficiency of the branched-chain α-keto acid dehydrogenase complex activity which leads to the accumulation of branched-chain amino acids (BCAA) leucine (Leu), isoleucine and valine and their respective α-keto-acids in body fluids. The main symptomatology presented by MSUD patients includes ketoacidosis, failure to thrive, poor feeding, apnea, ataxia, seizures, coma, psychomotor delay and mental retardation, but, the neurological pathophysiologic mechanisms are poorly understood. The treatment consists of a low protein diet and a semi-synthetic formula restricted in BCAA and supplemented with essential amino acids. It was verified that MSUD patients present L-carnitine (L-car) deficiency and this compound has demonstrated an antioxidant and anti-inflammatory role in metabolic diseases. Since there are no studies in the literature reporting the inflammatory profile of MSUD patients and the L-car role on the inflammatory response in this disorder, the present study evaluates the effect of L-car supplementation on plasma inflammatory cytokines interleukin-1ß (IL-1ß), interleukin-6 (IL-6), interferon-gamma (INF-É£), and a correlation with malondialdehyde (MDA), as a marker of oxidative damage, and with free L-car plasma levels in treated MSUD patients. Significant increases of IL-1ß, IL-6, and INF-É£ were observed before the treatment with L-car. Moreover, there is a negative correlation between all cytokines tested and L-car concentrations and a positive correlation among the MDA content and IL-1ß and IL-6 values. Our data show that L-car supplementation can improve cellular defense against inflammation and oxidative stress in MSUD patients and may represent an additional therapeutic approach to the patients affected by this disease.


Subject(s)
Carnitine/therapeutic use , Dietary Supplements , Inflammation Mediators/blood , Maple Syrup Urine Disease/blood , Maple Syrup Urine Disease/drug therapy , Child , Child, Preschool , Female , Humans , Inflammation/blood , Inflammation/drug therapy , Male
5.
Mutat Res ; 775: 43-7, 2015 May.
Article in English | MEDLINE | ID: mdl-25867118

ABSTRACT

Maple syrup urine disease (MSUD) is an inherited disorder caused by severe deficient activity of the branched-chain α-keto acid dehydrogenase complex involved in the degradation pathway of branched-chain amino acids (BCAAs) and their α-ketoacid derivatives. MSUD patients generally present ketoacidosis, poor feeding, ataxia, coma, psychomotor delay, mental retardation and brain abnormalites. Treatment consists of dietary restriction of the BCAA (low protein intake) supplemented by a BCAA-free amino acid mixture. Although the mechanisms of brain damage in MSUD are poorly known, previous studies have shown that oxidative stress may be involved in the neuropathology of this disorder. In this regard, it was recently reported that MSUD patients have deficiency of l-carnitine (l-car), a compound with antioxidant properties that is used as adjuvant therapy in various inborn errors of metabolism. In this work, we investigated DNA damage determined by the alkaline comet assay in peripheral whole blood leukocytes of MSUD patients submitted to a BCAA-restricted diet supplemented or not with l-car. We observed a significant increase of DNA damage index (DI) in leukocytes from MSUD patients under BCAA-restricted diet as compared to controls and that l-car supplementation significantly decreased DNA DI levels. It was also found a positive correlation between DI and MDA content, a marker of lipid peroxidation, and an inverse correlation between DI and l-car levels. Taken together, our present results suggest a role for reactive species and the involvement of oxidative stress in DNA damage in this disorder. Since l-car reduced DNA damage, it is presumed that dietary supplementation of this compound may serve as an adjuvant therapeutic strategy for MSUD patients in addition to other therapies.


Subject(s)
Carnitine/administration & dosage , DNA Damage , Leukocytes/metabolism , Maple Syrup Urine Disease/drug therapy , Maple Syrup Urine Disease/metabolism , Oxidative Stress/drug effects , Vitamin B Complex/administration & dosage , Child , Child, Preschool , Female , Humans , Leukocytes/pathology , Male , Maple Syrup Urine Disease/genetics , Maple Syrup Urine Disease/pathology
6.
Int J Dev Neurosci ; 42: 10-4, 2015 May.
Article in English | MEDLINE | ID: mdl-25680940

ABSTRACT

Maple syrup urine disease (MSUD) is a disorder of branched-chain amino acids (BCAA). The defect in the branched-chain α-keto acid dehydrogenase complex activity leads to an accumulation of these compounds and their corresponding α-keto-acids and α-hydroxy-acids. Studies have shown that oxidative stress may be involved in neuropathology of MSUD. L-carnitine (L-car), which has demonstrated an important role as antioxidant by reducing and scavenging free radicals formation and by enhancing the activity of antioxidant enzymes, have been used in the treatment of some metabolic rare disorders. This study evaluated the oxidative stress parameters, di-tyrosine, isoprostanes and antioxidant capacity, in urine of MSUD patients under protein-restricted diet supplemented or not with L-car capsules at a dose of 50 mg kg(-1) day(-1). It was also determined urinary α-keto isocaproic acid levels as well as blood free L-car concentrations in blood. It was found a deficiency of carnitine in patients before the L-car supplementation. Significant increases of di-tyrosine and isoprostanes, as well as reduced antioxidant capacity, were observed before the treatment with L-car. The L-car supplementation induced beneficial effects on these parameters reducing the di-tyrosine and isoprostanes levels and increasing the antioxidant capacity. It was also showed a significant increase in urinary of α-ketoisocaproic acid after 2 months of L-car treatment, compared to control group. In conclusion, our results suggest that L-car may have beneficial effects in the treatment of MSUD by preventing oxidative damage to the cells and that urine can be used to monitorize oxidative damage in patients affected by this disease.


Subject(s)
Biomarkers/urine , Dietary Supplements , Maple Syrup Urine Disease/urine , Amino Acids/urine , Analysis of Variance , Antioxidants/metabolism , Child , Child, Preschool , Dinoprost/analogs & derivatives , Enzyme-Linked Immunosorbent Assay , Female , Humans , Isoprostanes/urine , Keto Acids/urine , Male , Maple Syrup Urine Disease/diet therapy , Tandem Mass Spectrometry , Tyrosine/urine
7.
Mol Neurobiol ; 51(3): 1184-94, 2015.
Article in English | MEDLINE | ID: mdl-24961569

ABSTRACT

Tyrosine accumulates in inborn errors of tyrosine catabolism, especially in tyrosinemia type II. In this disease caused by tyrosine aminotransferase deficiency, eyes, skin, and central nervous system disturbances are found. In the present study, we investigated the chronic effect of tyrosine methyl ester (TME) and/or creatine plus pyruvate on some parameters of oxidative stress and enzyme activities of phosphoryltransfer network in cerebral cortex homogenates of 21-day-old Wistar. Chronic administration of TME induced oxidative stress and altered the activities of adenylate kinase and mitochondrial and cytosolic creatine kinase. Total sulfhydryls content, GSH content, and GPx activity were significantly diminished, while DCFH oxidation, TBARS content, and SOD activity were significantly enhanced by TME. On the other hand, TME administration decreased the activity of CK from cytosolic and mitochondrial fractions but enhanced AK activity. In contrast, TME did not affect the carbonyl content and PK activity in cerebral cortex of rats. Co-administration of creatine plus pyruvate was effective in the prevention of alterations provoked by TME administration on the oxidative stress and the enzymes of phosphoryltransfer network, except in mitochondrial CK, AK, and SOD activities. These results indicate that chronic administration of TME may stimulate oxidative stress and alter the enzymes of phosphoryltransfer network in cerebral cortex of rats. In case this also occurs in the patients affected by these disorders, it may contribute, along with other mechanisms, to the neurological dysfunction of hypertyrosinemias, and creatine and pyruvate supplementation could be beneficial to the patients.


Subject(s)
Cerebral Cortex/enzymology , Creatine/pharmacology , Oxidative Stress/physiology , Pyruvic Acid/pharmacology , Transferases/metabolism , Tyrosine/pharmacology , Animals , Cerebral Cortex/drug effects , Enzyme Activation/drug effects , Enzyme Activation/physiology , Male , Oxidative Stress/drug effects , Phosphorylation/drug effects , Phosphorylation/physiology , Rats , Rats, Wistar , Tyrosine/analogs & derivatives
8.
Gene ; 548(2): 294-8, 2014 Sep 15.
Article in English | MEDLINE | ID: mdl-25046137

ABSTRACT

Maple syrup urine disease (MSUD) is an inherited aminoacidopathy caused by a deficiency in branched-chain α-keto acid dehydrogenase complex activity that leads to the accumulation of the branched-chain amino acids (BCAAs) leucine (Leu), isoleucine, and valine and their respective α-keto-acids, α-ketoisocaproic acid (KIC), α keto-ß-methylvaleric acid, and α-ketoisovaleric acid. The major clinical features presented by MSUD patients include ketoacidosis, failure to thrive, poor feeding, apnea, ataxia, seizures, coma, psychomotor delay, and mental retardation; however, the pathophysiology of this disease is poorly understood. MSUD treatment consists of a low protein diet supplemented with a mixture containing micronutrients and essential amino acids but excluding BCAAs. Studies have shown that oxidative stress may be involved in the neuropathology of MSUD, with the existence of lipid and protein oxidative damage in affected patients. In recent years, studies have demonstrated the antioxidant role of L-carnitine (L-Car), which plays a central function in cellular energy metabolism and for which MSUD patients have a deficiency. In this work, we investigated the in vitro effect of Leu and KIC in the presence or absence of L-Car on DNA damage in peripheral whole blood leukocytes using the alkaline comet assay with silver staining and visual scoring. Leu and KIC resulted in a DNA damage index that was significantly higher than that of the control group, and L-Car was able to significantly prevent this damage, mainly that due to KIC.


Subject(s)
Carnitine/pharmacology , DNA Damage/drug effects , Keto Acids/metabolism , Leucine/metabolism , Maple Syrup Urine Disease/metabolism , Vitamin B Complex/pharmacology , Comet Assay , Energy Metabolism/drug effects , Humans , Leukocytes/metabolism , Maple Syrup Urine Disease/pathology , Oxidative Stress
9.
Metab Brain Dis ; 28(4): 541-50, 2013 Dec.
Article in English | MEDLINE | ID: mdl-23657560

ABSTRACT

Hyperphenylalaninemia (HPA) leads to increased oxidative stress in patients with phenylketonuria (PKU) and in animal models of PKU. Early diagnosis and immediate adherence to a phenylalanine-restricted diet prevents HPA and, consequently, severe brain damage. However, treated adolescent and adult PKU patients have difficulties complying with the diet, leading to an oscillation of phenylalanine levels and associated oxidative stress. The brain is especially susceptible to reactive species, and oxidative stress might add to the impaired cognitive function found in these patients. The restricted PKU diet has a very limited nutrient content from natural foods and almost no animal protein, which reduces the intake of important compounds. These specific compounds can act as scavengers of reactive species and can be co-factors of antioxidant enzymes. Supplementation with nutrients, vitamins, and tetrahydropterin has given quite promising results in patients and animal models. Antioxidant supplementation has been studied in HPA, however there is no consensus about its always beneficial effects. In this way, regular exercise could be a beneficial addition on antioxidant status in PKU patients. A deeper understanding of PKU molecular biochemistry, and genetics, as well as the need for improved targeted treatment options, could lead to the development of new therapeutic strategies.


Subject(s)
Antioxidants/therapeutic use , Brain/drug effects , Dietary Supplements , Oxidative Stress/drug effects , Phenylketonurias/drug therapy , Antioxidants/pharmacology , Brain/metabolism , Diet , Humans , Phenylketonurias/metabolism
10.
Int J Dev Neurosci ; 31(1): 21-4, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23137711

ABSTRACT

Maple syrup urine disease (MSUD) is an inborn error of metabolism biochemically characterized by elevated levels of the branched chain amino acids (BCAA) leucine, isoleucine, valine and the corresponding branched-chain α-keto acids. This disorder is clinically characterized by ketoacidosis, seizures, coma, psychomotor delay and mental retardation whose pathophysiology is not completely understood. Recent studies have shown that oxidative stress may be involved in neuropathology of MSUD. l-Carnitine (l-Car) plays a central role in the cellular energy metabolism because it transports long-chain fatty acids for oxidation and ATP generation. In recent years many studies have demonstrated the antioxidant role of this compound. In this work, we investigated the effect of BCAA-restricted diet supplemented or not with l-Car on lipid peroxidation and in protein oxidation in MSUD patients. We found a significant increase of malondialdehyde and of carbonyl content in plasma of MSUD patients under BCAA-restricted diet compared to controls. Furthermore, patients under BCAA-restricted diet plus l-Car supplementation presented a marked reduction of malondialdehyde content in relation to controls, reducing the lipid peroxidation. In addition, free l-Car concentrations were negatively correlated with malondialdehyde levels. Our data show that l-Car may have an antioxidant effect, protecting against the lipid peroxidation and this could represent an additional therapeutic approach to the patients affected by MSUD.


Subject(s)
Carnitine/therapeutic use , Lipid Metabolism/drug effects , Maple Syrup Urine Disease/drug therapy , Maple Syrup Urine Disease/metabolism , Proteins/metabolism , Vitamin B Complex/therapeutic use , Amino Acids/metabolism , Analysis of Variance , Child , Child, Preschool , Female , Humans , Male , Malondialdehyde/metabolism , Protein Carbonylation/drug effects
11.
Metab Brain Dis ; 27(1): 79-89, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22101931

ABSTRACT

Phenylketonuria is characterized by a variable degree of mental retardation and other neurological features whose mechanisms are not fully understood. In the present study we investigated the effect of intrahippocampal administration of phenylalanine, isolated or associated with pyruvate or creatine, on rat behavior and on oxidative stress. Sixty-day-old male Wistar rats were randomly divided into 6 groups: saline; phenylalanine; pyruvate; creatine; phenylalanine + pyruvate; phenylalanine + creatine. Phenylalanine was administered bilaterally in the hippocampus one hour before training; pyruvate, at the same doses, was administered in the hippocampus one hour before phenylalanine; creatine was administered intraperitoneally twice a day for 5 days before training; controls received saline solution at same volumes than the other substances. Parameters of exploratory behavior and of emotionality were assessed in both training and test sessions in the open field task. Rats receiving phenylalanine did not habituate to the open field along the sessions, indicating deficit of learning/memory, but parameters of emotionality were normal, not interfering in the habituation process. Pyruvate or creatine administration prevented the lack of habituation caused by phenylalanine. Pyruvate and creatine also prevented alterations provoked by phenylalanine on lipid peroxidation, total content of sulfhydryls, total radical-trapping antioxidant potential and total antioxidant reactivity. The results suggest that the behavioral alterations provoked by intra-hippocampal administration of phenylalanine may be caused, at least in part, by oxidative stress and/or energy deficit. If this also occurs in PKU, it is possible that pyruvate and creatine supplementation to the phenylalanine-restricted diet might be beneficial to phenylketonuric patients.


Subject(s)
Creatine/administration & dosage , Hippocampus/drug effects , Oxidative Stress/drug effects , Phenylalanine/adverse effects , Phenylketonurias/metabolism , Pyruvic Acid/administration & dosage , Animals , Antioxidants/pharmacology , Energy Metabolism/drug effects , Exploratory Behavior/drug effects , Habituation, Psychophysiologic/drug effects , Hippocampus/metabolism , Humans , Lipid Peroxidation/drug effects , Male , Phenylalanine/administration & dosage , Phenylketonurias/pathology , Rats , Rats, Wistar
12.
J Neurol Sci ; 292(1-2): 89-95, 2010 May 15.
Article in English | MEDLINE | ID: mdl-20226470

ABSTRACT

Phenylketonuria (PKU) is a recessive autosomal disorder caused by a severe deficiency of phenylalanine-4-hydroxilase activity which leads to the accumulation of L-phenylalanine (Phe) in the tissues and plasma of patients. The main clinical features are retarded development and intellectual impairment. Recent studies have shown that oxidative stress may be involved in neuropathology of hyperphenylalaninemia. Lipoic acid (LA) is considered a potent antioxidant which is well absorbed from diet and can easily cross the blood-brain barrier. We investigated the neuroprotective effects of lipoic acid against oxidative stress caused by Phe in vivo and in vitro. Lipoic acid prevented the inhibition provoked by Phe on the activities of catalase, superoxide dismutase, glutathione peroxidase, and glucose-6-phosphate dehydrogenase. It also prevented Phe alterations on total radical-trapping antioxidant potential, thiobarbituric acid-reactive substances, glutathione concentration and on production of reactive species. It is concluded that lipoic acid may be an efficient antioxidant in the CNS against oxidative stress induced by hyperphenylalaninemia. If the present results are confirmed in PKU patients, it is possible that supplementation of lipoic acid may contribute to the treatment of PKU as an adjuvant therapeutic approach to Phe-restricted dietary treatment and amino acid mixture.


Subject(s)
Brain/drug effects , Oxidative Stress/drug effects , Phenylketonurias/metabolism , Thioctic Acid/pharmacology , Analysis of Variance , Animals , Antioxidants/pharmacology , Brain/metabolism , Catalase/metabolism , Glucosephosphate Dehydrogenase/metabolism , Glutathione Peroxidase/metabolism , Phenylalanine , Phenylketonurias/chemically induced , Rats , Rats, Wistar , Superoxide Dismutase/metabolism
13.
J Nat Prod ; 68(5): 784-6, 2005 May.
Article in English | MEDLINE | ID: mdl-15921431

ABSTRACT

Two new benzophenones were isolated from the leaves of Hypericum carinatum. Their structures were established on the basis of 2D NMR spectroscopic analyses and mass spectrometry as cariphenone A (6-benzoyl-5,7-dihydroxy-2,2,8-trimethyl-2H-chromene) (1) and cariphenone B (8-benzoyl-5,7-dihydroxy-2,2,6-trimethyl-2H-chromene) (2). Five known compounds, the phloroglucinol derivative uliginosin B (3), 1-eicosanol, sitosterol, stigmasterol, and campesterol, were also characterized. Compounds 1-3 were evaluated for their total antioxidant capacity through a total radical-trapping parameter assay. Only compound 1 showed moderate antioxidant activity, exhibiting inhibition of chemiluminescence similar to that of quercetin at the same concentration.


Subject(s)
Antioxidants/isolation & purification , Benzophenones/isolation & purification , Hypericum/chemistry , Plants, Medicinal/chemistry , Antioxidants/chemistry , Antioxidants/pharmacology , Benzophenones/chemistry , Benzophenones/pharmacology , Brazil , Dose-Response Relationship, Drug , Luminescent Measurements , Molecular Structure , Phloroglucinol/analogs & derivatives , Phloroglucinol/chemistry , Phloroglucinol/isolation & purification , Plant Leaves/chemistry , Quercetin/pharmacology
14.
Int J Dev Neurosci ; 21(3): 145-51, 2003 May.
Article in English | MEDLINE | ID: mdl-12711352

ABSTRACT

Maple syrup urine disease (MSUD) is a metabolic disorder biochemically characterized by the accumulation of branched-chain alpha-amino acids (BCAA) and their branched-chain alpha-keto acids (BCKA) in blood and tissues. Neurological dysfunction is usually present in the patients, but the mechanisms of brain damage in this disease are far from be understood. The main objective of this study was to investigate the mechanisms by which BCAA inhibit creatine kinase activity, a key enzyme of energy homeostasis, in the brain cortex of 21-day-old Wistar rats. For the kinetic studies, Lineweaver-Burk and a modification of the Chevillard et al. plots were used to characterize the mechanisms of enzyme inhibition. The results indicated that BCAA inhibit creatine kinase by competition with the substrates phosphocreatine and ADP at the active site. Considering the crucial role creatine kinase plays in energy homeostasis in brain, if these effects also occur in the brain of MSUD patients, it is possible that inhibition of this enzyme activity may contribute to the brain damage found in this disease. In this case, it is possible that creatine supplementation to the diet might benefit MSUD patients.


Subject(s)
Amino Acids, Branched-Chain/metabolism , Amino Acids/pharmacology , Creatine Kinase/antagonists & inhibitors , Creatine Kinase/metabolism , Maple Syrup Urine Disease/enzymology , Amino Acids/chemistry , Amino Acids, Branched-Chain/chemistry , Animals , Cerebral Cortex , Creatine Kinase/chemistry , Enzyme Activation , Isoleucine/chemistry , Isoleucine/pharmacology , Keto Acids/metabolism , Kinetics , Leucine/chemistry , Leucine/pharmacology , Maple Syrup Urine Disease/metabolism , Rats , Rats, Wistar , Reference Values , Valine/chemistry , Valine/pharmacology
15.
Brain Res ; 968(2): 199-205, 2003 Apr 11.
Article in English | MEDLINE | ID: mdl-12663089

ABSTRACT

Pyruvate kinase plays a crucial role on the glycolytic pathway, the main route that provides energy for brain functioning. In the present study, we investigated the kinetics of the inhibition of pyruvate kinase provoked by phenylalanine and its main metabolite, phenylpyruvate, in mitochondria-free cerebral cortex homogenate from 22-day-old Wistar rats. We found that phenylalanine and phenylpyruvate inhibit PK activity by competition with the enzyme substrates ADP and phosphoenolpyruvate. We also investigated the interaction between phenylalanine and phenylpyruvate, and the kinetics of alanine prevention of the inhibitory action of phenylalanine and phenylpyruvate on pyruvate kinase activity. We observed that alanine per se had no effect on PK activity but prevented the inhibitory action of phenylalanine and phenylpyruvate by competition. The data suggest that phenylalanine, phenylpyruvate, and alanine act on a common site in the enzyme, probably an allosteric one. It is possible that inhibition of brain PK activity may be related to the reduction of glucose metabolism observed in the brain of phenylketonuric patients and may be one of the mechanisms responsible for the neurological dysfunction found in these patients. Further studies, however, are necessary to evaluate the benefit of carbohydrate and alanine supplementation to the diet of phenylketonuric patients.


Subject(s)
Cerebral Cortex/drug effects , Neural Inhibition/drug effects , Phenylalanine/pharmacology , Phenylpyruvic Acids/pharmacology , Pyruvate Kinase/metabolism , Adenosine Diphosphate/pharmacology , Alanine/pharmacology , Animals , Binding, Competitive , Cerebral Cortex/enzymology , Cerebral Cortex/metabolism , Dose-Response Relationship, Drug , Drug Interactions , In Vitro Techniques , Phosphoenolpyruvate/pharmacology , Pyruvate Kinase/antagonists & inhibitors , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL